Prostate Cancer
Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System
November 9, 2023
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
November 9, 2023
Burden of prostate cancer in the Middle East: A comparative analysis based on global cancer observatory data.
November 9, 2023
Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.
November 9, 2023
Antihormonal-Treatment Status Affects 68Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
November 8, 2023
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity Against Prostate Cancer.
November 8, 2023
Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.
November 8, 2023
Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges.
November 8, 2023
Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer.
November 8, 2023
Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsyproven radio-recurrent localized prostate cancer.
November 8, 2023